CFO Kristian Borbos to leave Ascelia Pharma


Ascelia Pharma AB (publ) (ticker: ACE) today announced that CFO Kristian Borbos will leave the company to take up a similar position at the Danish biotech company Gubra.

Kristian Borbos joined Ascelia Pharma in 2017 and was instrumental in the company’s successful listing process to the main list of Nasdaq Stockholm in 2019.

“Kristian Borbos has played an important role in developing Ascelia Pharma into a Nasdaq listed company as well as building the capabilities that are essential for a well-functioning publicly traded company. I want to thank him for all his contributions and wish him success in his new role, knowing that he leaves behind a well-financed Ascelia Pharma with significant growth opportunities ahead”, said Magnus Corfitzen, CEO of Ascelia Pharma.

Ascelia Pharma will initiate the process to find a successor. Kristian Borbos will continue in the role as CFO for Ascelia Pharma during the resignation period.